KalVista Pharmaceuticals, Inc. (KALV)

Market Cap	632.06M
Revenue (ttm)	n/a
Net Income (ttm)	-126.64M
Shares Out	42.74M
EPS (ttm)	-3.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214,795
Open	14.57
Previous Close	14.39
Day's Range	14.52 - 14.93
52-Week Range	7.21 - 16.88
Beta	0.91
Analysts	Strong Buy
Price Target	24.00 (+62.27%)
Earnings Date	Jul 11, 2024

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID f...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Benjamin L. Palleiko
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV

Analyst Forecast

According to 3 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is $24.0, which is an increase of 62.27% from the latest price.

Price Target

$24.0

(62.27% upside)

Analyst Consensus: Strong Buy